Dako and Merck to Collaborate on Diagnostic Tests for Cancer Treatment

Dako, an Agilent company, has entered into an agreement with Merck to develop companion diagnostic tests for oncology drugs currently in Merck’s development pipeline.

The market for companion diagnostics is steadily growing, as  personalized medicine has the potential to improve patient care and manage healthcare costs by targeting treatments to individuals likely to benefit from specific therapies.

Dako collaborates with many top-tier pharma companies to develop companion diagnostics, including Bristol-Myers Squibb and Genentech, a member of the Roche Group.


For more information go to:

Dako to Collaborate with Merck on Development of Companion Diagnostics for Cancer Treatment

Dako home page